跳至主要内容
临床试验/NCT02510378
NCT02510378Unknown2 期

Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases

Chinese Academy of Medical Sciences3 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2014年1月最近更新:
适应症

试验速览

阶段
2 期
入组人数
47
试验地点
3
主要终点
percentage of patients undergo R0 surgery during the follow-up

研究概览

简要总结

Patients with rectal cancer and resectable liver metastases receive short course radiotherapy(5Gy/f x 5f) to the pelvis and XELOX consolidating chemotherapy al least 4 cycles after 2 weeks.

详细描述

Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.

After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed primary carcinoma of the rectum (Lower border of tumour ≤ 10 cm from anal verge) locally advanced stage in primary site of rectum resectable synchronous liver metastases. The decision of resectable liver metastases will be made at multidisciplinary clinical meetings.

排除标准

  • Obstruction of the gastrointestinal tract Previously constructed stoma prior radiotherapy of the pelvis

结局指标

主要结局

percentage of patients undergo R0 surgery during the follow-up

时间窗: 3 months

次要结局

  • The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hua Ren

Attending physician

Chinese Academy of Medical Sciences

研究点 (3)

Loading locations...

相似试验